SAN DIEGO, CA November 16, 2006/MarketWire/– Aegis Therapeutics, a leader in intranasal drug delivery, will present a talk entitled: “High-Efficiency Transmucosal Delivery of Peptide and Protein Therapeutics” at the 2nd Modern Drug Discovery & Development Summit presented by GTCbio. Dr. Edward T. Maggio, President and CEO of Aegis, will describe the application of Aegis’ Intravail™ non-invasive drug delivery technology, and Aegis’ ProTek™ protein stabilization technology to specific peptide and protein therapeutics. The presentation is scheduled for Tuesday, December 5, 2006 at the Pennsylvania Convention Center, Philadelphia, PA.
Information about the conference may be obtained from the following website: http://gtcbio.com/confpage.asp?cid=8
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis’ Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Our ProTek™ technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek™ technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.
For more information about Aegis, please visit the Aegis website at: htpp://www.aegisthera.com.